Hematopoietic Stem Cell TransplantationTransplantation, HomologousGraft vs Host DiseaseTransplantation ConditioningHematopoietic Stem CellsHematologic NeoplasmsStem Cell TransplantationTransplantation, AutologousGraft vs Leukemia EffectPeripheral Blood Stem Cell TransplantationTransplantation ChimeraTissue DonorsMyeloablative AgonistsTreatment OutcomeBone Marrow TransplantationRecurrenceBusulfanGraft vs Tumor EffectHistocompatibilityChimerismRetrospective StudiesWhole-Body IrradiationLeukemiaHistocompatibility TestingStem CellsVidarabineAllograftsGraft SurvivalHematologic DiseasesCord Blood Stem Cell TransplantationLeukemia, Myeloid, AcuteMyelodysplastic SyndromesSiblingsLymphocyte TransfusionHLA AntigensRemission InductionImmunosuppressive AgentsPrecursor Cell Lymphoblastic Leukemia-LymphomaHepatic Veno-Occlusive DiseaseSurvival RateCytomegalovirus InfectionsSurvival AnalysisTime FactorsAcute DiseaseCombined Modality TherapyLeukemia, Myelogenous, Chronic, BCR-ABL PositiveTransplantation ImmunologyDisease-Free SurvivalLeukemic InfiltrationCystitisAnemia, AplasticTransplantation, IsogeneicT-LymphocytesMinor Histocompatibility AntigensLymphocyte DepletionHematopoiesisOpportunistic InfectionsNeoplasm, ResidualFollow-Up StudiesMultiple MyelomaHematopoietic Stem Cell MobilizationSalvage TherapySevere Combined ImmunodeficiencyFlow CytometryCyclophosphamideLymphoproliferative DisordersAntilymphocyte SerumAntigens, CD34CytomegalovirusBronchiolitis ObliteransBone Marrow CellsRisk FactorsLiver TransplantationMice, Inbred C57BLImmunocompromised HostPrognosisBlood Group IncompatibilityPhotopheresisMycosesCell DifferentiationAntineoplastic Combined Chemotherapy ProtocolsLeukemia, MyeloidImmunosuppressionFatal OutcomeSurvivorsPrimary MyelofibrosisMesenchymal Stem Cell TransplantationGanciclovirUnrelated DonorsFetal BloodCell TransplantationCytarabineCell LineageChronic DiseaseIsoantigensIncidenceStem Cell NicheCyclosporineGraft RejectionProspective Studies